Schering-Plough News
Most Popular Schering-Plough Story
Merck tracks positive results, bleeding risk in second big vorapaxar study
Merck says that vorapaxar, its troubled blood thinner once considered the jewel in Schering-Plough's crown when the pharma giant bought it for $41 billion, hit its primary efficacy endpoint in a Read more...
Latest Headlines
- April 28, 2010
- February 18, 2010
- February 1, 2010
- August 31, 2009
- August 14, 2009
- August 13, 2009
- July 31, 2009
- April 23, 2009
- April 13, 2009
- March 9, 2009
- February 9, 2009
- January 14, 2009
- August 4, 2008
- August 1, 2008
- July 30, 2008
- July 9, 2008
- June 30, 2008
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
